Research programme: smoking cessation therapeutics - Astraea TherapeuticsAlternative Names: AT-1001; AT-1012
Latest Information Update: 04 Jul 2016
At a glance
- Originator Astraea Therapeutics
- Class Nicotine replacement therapy
- Mechanism of Action Nicotinic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Smoking withdrawal